Evidence map›Paper›PMID 41532847›Full record

ArticleCancer discovery2026

Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence.

Kie Kyon Huang, Takeshi Hagihara, Benedict Shi Xiang Lian, Zhi Xuan Ong, Shen Kiat Lim, Roxanne Hui Heng Chong, Supriya Srivastava, Jason Xing Kang, May Yin Lee, Angie Lay-Keng Tan and 29 more

Abstract read
In one paragraph

Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Kie Kyon Huang *Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0003-4104-8951
Takeshi Hagihara *Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0009-0007-9263-1553
Benedict Shi Xiang LianProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0002-3467-5394
Zhi Xuan OngProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0009-0000-7079-5900
Shen Kiat LimProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0003-4464-3609
Roxanne Hui Heng ChongDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-7640-2052
Supriya SrivastavaDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-6727-3076
Jason Xing KangLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.ORCID 0000-0002-8072-015X
May Yin LeeGenome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.ORCID 0000-0003-2366-9463
Angie Lay-Keng TanProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0002-8238-0515
Minghui LeeProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0009-0005-3261-5178
Shamaine Wei Ting HoGenome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.ORCID 0000-0002-2595-0710
Siti Aishah Binte Abdul GhaniProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0003-2317-0179
Clara Shi Ya NgProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0009-0000-2090-1955
Ruanyi LiangProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0009-0003-3741-7854
Lin LiuDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0009-0003-4351-3201
Su Ting TayProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0003-3609-0143
Xuewen OngProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0009-0000-4518-5166
Feng ZhuDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0001-6030-9251
Hui ChenMGI Tech Singapore Pte. Ltd., Singapore, Singapore.ORCID 0009-0004-9396-0023
Zhen LiMGI Tech Singapore Pte. Ltd., Singapore, Singapore.ORCID 0009-0002-0543-3377
Tiing Leong AngDepartment of Gastroenterology & Hepatology, Changi General Hospital, Singapore, Singapore.ORCID 0000-0001-9993-8549
Takuji GotodaCancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID 0000-0001-6904-6777
Robert J HuangDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-0891-7409
Christopher J L KhorProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0002-1409-5691
Hyun-Soo KimDepartment of Internal Medicine, Yonsei University Wonju College of Medicine, Seoul, Korea.ORCID 0000-0001-7190-0362
Louis Ho Shing LauDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.ORCID 0000-0002-4163-4531
Yi-Chia LeeDepartment of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-8160-1216
Ayaka TakasuCancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID 0000-0003-0130-7170
Ming TehDepartment of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0001-6879-8678
Mann Yie ThianDepartment of Gastroenterology & Hepatology, Tan Tock Seng Hospital, Singapore, Singapore.ORCID 0009-0001-6495-2938
Wai Leong TamGenome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.ORCID 0000-0003-2365-5264
Xin LuLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-6587-1152
Sunny H WongLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.ORCID 0000-0002-3354-9310
Jimmy B Y SoDepartment of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-9772-7905
Hyunsoo ChungDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0001-5159-357X
Jonathan LeeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0001-7065-8041
Khay Guan YeohDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0002-7802-4606
Patrick TanProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0002-0179-8048

Funding

Agency for Science, Technology and Research (A*STAR)Cancer Science Institute of Singapore, National University of Singapore (CSI)Duke-NUS Medical School (DukeNUS)Ministry of Education - Singapore (MOE) MOE-MOET32021-0004National Medical Research Council (NMRC) MOH-000967National Research Foundation Singapore (NRF) MOH-OFLCG18May-0003National University of Singapore (NUS) NUHSRO/2022/071/NUSMed/Microbiome/LOA
6 · The paper itself

Abstract

Intestinal metaplasia (IM) is a premalignant condition associated with increased risk of gastric cancer-a deadly malignancy with varying geographic incidence. High-depth targeted sequencing of more than 1,500 IM samples from six countries identified 47 significantly mutated genes, including driver genes associated with high-risk populations and worse prognosis (ARID1A), KRAS/MAPK signaling (KRAS, BRAF, MAP2K1, MAP3K1, and MAP2K4), and altered mucosal immunity (PIGR). IM whole-genome sequencing and DNA methylation analysis revealed SBS17 as a specific mutational signature separating IMs from normal gastric tissues, associated with late DNA replication, genomic hypomethylation, and tobacco exposure. Beyond epithelial-derived somatic mutations, we observed elevated clonal hematopoiesis (CH) in patients with IM associated with age, smoking, and enhanced risk of progressing to gastric cancer. Patients with CH expansions exhibited co-occurring IM PIGR truncating mutations and greater colonization of the IM microenvironment by orally derived bacteria, suggesting that CH may promote IM progression by modulating host-microbe mucosal immunity. SIGNIFICANCE: This international study identifies recurrent IM driver genes, IM-specific mutational signatures, and alterations in IM-associated immune landscapes and microbiomes. Our results highlight a role for nonepithelial somatic alterations (CH) in IM progression to gastric cancer, offering new translational opportunities for early cancer detection and interception.

Indexed as

Clonal HematopoiesisMutationPrecancerous ConditionsStomach NeoplasmsFemaleHumansIncidenceMetaplasia

Identifiers

PMID41532847
PMCPMC13056296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.